Proview Technology (Shenzhen) Co., Ltd
("Proview") has accused Apple of
infringement over its exclusive right to the "ipad" name,
and requested Apple to stop its trademark infringement immediately,
otherwise it would work with 8 creditor banks including Bank of
China to ask relevant authorities to seize Apple's infringing
Proview is a HK listed company wholly invested by Proview
International, and is mainly engaged in developing and producing
CRT displays, LCD TVs and their fittings and accessories.
Proview International registered "ipad" trademark in
EU, China, Korea, Singapore, Indonesia and other countries from
2000 to 2004, and transferred the trademark in EU to Apple early
2010. But it said Proview still held the mark in China. However,
Apple claims it has taken all the "ipad" trademarks
including the one registered in China based on the agreement made
between Proview International and Apple. The case was brought to
court in May 2010, and is still being heard in Hong Kong.
Apple is one of the companies who use similar names for their
core products (iPad, iPhone, iPod), making up what some call a
family of marks. The advantage of having a trademark family is that
the consumers will easily associate the new product name with the
old ones and hence reinforce the whole family names that enjoy the
goodwill of Apple. The disadvantage is that it will be easy for
competitors or trademark squatters to anticipate the future product
name for preemptive filing.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
This article enunciates the recent, much awaited, and landmark judgment delivered on September 16, 2016 by Hon'ble Delhi High Court throwing light on the important provisions of the Copyright Act, 1962.
The Patents Act 1970, along with the Patents Rules 1972, came into force on 20th April 1972, replacing the Indian Patents and Designs Act 1911. The Patents Act was largely based on the recommendations of the Ayyangar Committee Report headed by Justice N. Rajagopala Ayyangar. One of the recommendations was the allowance of only process patents with regard to inventions relating to drugs, medicines, food and chemicals.
The Policy stresses on the need for a holistic approach to be taken on legal, administrative, institutional and enforcement issues related to IP.
Some comments from our readers… “The articles are extremely timely and highly applicable” “I often find critical information not available elsewhere” “As in-house counsel, Mondaq’s service is of great value”
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).